Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (41)

Advertisement

Research Article Free access | 10.1172/JCI108820

The Mitogenic Effect of the Lymphocytosis Promoting Factor from Bordetella Pertussis on Human Lymphocytes

J. H. Morse, A. S. Kong, J. Lindenbaum, and S. I. Morse

Department of Medicine, College of Physicians & Surgeons, Columbia University, New York 10032

Department of Microbiology and Immunology, State University of New York Downstate Medical Center, Brooklyn, New York 11203

Find articles by Morse, J. in: PubMed | Google Scholar

Department of Medicine, College of Physicians & Surgeons, Columbia University, New York 10032

Department of Microbiology and Immunology, State University of New York Downstate Medical Center, Brooklyn, New York 11203

Find articles by Kong, A. in: PubMed | Google Scholar

Department of Medicine, College of Physicians & Surgeons, Columbia University, New York 10032

Department of Microbiology and Immunology, State University of New York Downstate Medical Center, Brooklyn, New York 11203

Find articles by Lindenbaum, J. in: PubMed | Google Scholar

Department of Medicine, College of Physicians & Surgeons, Columbia University, New York 10032

Department of Microbiology and Immunology, State University of New York Downstate Medical Center, Brooklyn, New York 11203

Find articles by Morse, S. in: PubMed | Google Scholar

Published September 1, 1977 - More info

Published in Volume 60, Issue 3 on September 1, 1977
J Clin Invest. 1977;60(3):683–692. https://doi.org/10.1172/JCI108820.
© 1977 The American Society for Clinical Investigation
Published September 1, 1977 - Version history
View PDF
Abstract

The purified lymphocytosis promoting factor (LPF) from Bordetella pertussis was found to be a potent mitogen for peripheral blood lymphocytes (PBL) from normal adults as well as for cord blood lymphocytes. Proliferation occurred in autologous plasma or fetal calf serum, regardless of previous exposure to pertussis infection or immunization. Only one adult human serum, from a physician constantly working with B. pertussis, inhibited the mitogenic response to LPF and this serum was shown to contain precipitating antibody against LPF. The proliferative effect of LPF was characteristic of a “nonspecific” mitogen and not of antigen stimulation of sensitized cells.

LPF, phytohemagglutinin, and concanavalin A were approximately equal in potency although variation occurred depending upon the cell donor. Experiments with lymphocyte subpopulations obtained by rosetting techniques employing sheep erythrocytes, mouse erythrocytes, and sheep erythrocytes coated with antibody and complement suggested the requirement of a multicellular system for LPF mitogencity.

PBL from most patients with chronic lymphatic leukemia and lymphosarcoma cell leukemia were even less responsive to LPF than to phytohemagglutinin, whereas PBL from patients with lymphosarcoma usually responded to both mitogens. It can be inferred from the results of experiments with both normal and leukemic cells that LPF, which is a murine thymus-derived (T)-cell mitogen, is also a T-cell mitogen for human PBL. The exact cell requirement and mode of action, however, are as yet unknown.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 683
page 683
icon of scanned page 684
page 684
icon of scanned page 685
page 685
icon of scanned page 686
page 686
icon of scanned page 687
page 687
icon of scanned page 688
page 688
icon of scanned page 689
page 689
icon of scanned page 690
page 690
icon of scanned page 691
page 691
icon of scanned page 692
page 692
Version history
  • Version 1 (September 1, 1977): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (41)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts